SOURCE: BIOLASE Technology, Inc.

November 27, 2007 06:00 ET

BIOLASE Named to Deloitte's Orange County Technology Fast 50

IRVINE, CA--(Marketwire - November 27, 2007) - BIOLASE Technology, Inc. (NASDAQ: BLTI), the world's leading dental laser company, announced today that it was ranked #29 on Deloitte's 2007 Orange County Technology Fast 50.

The 2007 Orange County Technology Fast 50 is a ranking of the 50 fastest growing technology, media, telecommunications and life sciences companies in Orange County, CA, based on percentage of revenue growth from 2002-2006. As reported by Deloitte, BIOLASE experienced revenue growth of 156 percent from 2002-2006.

BIOLASE Interim CEO Federico Pignatelli said, "It is an honor to once again be named to the Fast 50. We are fortunate to have a team of talented and dedicated employees who contribute to the success of our Company. BIOLASE is the world leader in dental laser technology and offers a broad product line of innovative technologies that allow dentists to perform dental procedures with minimally invasive and clinically superior results."

Rick Rayson, Managing Partner, Orange County Practice, Deloitte & Touche LLP, commented, "Sustaining high revenue growth over five years is an exceptional accomplishment, and we commend BIOLASE for making the commitment to technology and delivering on the promise of market longevity. We are proud to honor BIOLASE to Deloitte's Technology Fast 50."

About the Technology Fast 50

To qualify for the Technology Fast 50, companies must have had operating revenues of at least $50,000 in 2002 and $5,000,000 in 2006, be headquartered in North America, and be a company that owns proprietary technology or proprietary intellectual property that contributes to a significant portion of the company's operating revenues; or devotes a significant proportion of revenues to the research and development of technology. Using other companies' technology or intellectual property in a unique way does not qualify.

About Deloitte

Deloitte refers to one or more of Deloitte Touche Tohmatsu, a Swiss Verein, its member firms and their respective subsidiaries and affiliates. As a Swiss Verein (association), neither Deloitte Touche Tohmatsu nor any of its member firms has any liability for each other's acts or omissions. Each of the member firms is a separate and independent legal entity operating under the names "Deloitte", "Deloitte & Touche", "Deloitte Touche Tohmatsu" or other related names. Services are provided by the member firms or their subsidiaries or affiliates and not by the Deloitte Touche Tohmatsu Verein.

Deloitte & Touche USA LLP is the US member firm of Deloitte Touche Tohmatsu. In the US, services are provided by the subsidiaries of Deloitte & Touche USA LLP (Deloitte & Touche LLP, Deloitte Consulting LLP, Deloitte Financial Advisory Services LLP, Deloitte Tax LLP and their subsidiaries), and not by Deloitte & Touche USA LLP.

About BIOLASE Technology, Inc.

BIOLASE Technology, Inc. (, the world's leading dental laser company, is a medical technology company that develops, manufactures and markets lasers and related products focused on technologies that advance the practice of dentistry and medicine. The Company's products incorporate patented and patent pending technologies designed to provide clinically superior performance with less pain and faster recovery times. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. Other products under development address ophthalmology and other medical and consumer markets.

This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by our management. These forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks, uncertainties and other factors which may cause the Company's actual results to differ materially from the statements contained herein, and are described in the Company's reports it files with the Securities and Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed on forward-looking statements. Such information is subject to change, and we undertake no obligation to update such statements.

Contact Information

  • For further information, please contact:
    Richard L. Harrison
    Executive Vice President and CFO
    BIOLASE Technology, Inc.

    Jill Bertotti
    Allen & Caron